Abstract

Genetic risk factors for Parkinson's disease (PD) risk and progression have been identified from genome-wide association studies (GWAS), as well as studies of familial forms of PD, implicating common variants at more than 90 loci and pathogenic or likely pathogenic variants at 16 loci. With the goal of understanding whether genetic variants at these PD-risk loci/genes differentially contribute to individual clinical phenotypic characteristics of PD, we used structured clinical documentation tools within the electronic medical record in an effort to provide a standardized and detailed clinical phenotypic characterization at the point of care in a cohort of 856 PD patients. We analyzed common SNPs identified in previous GWAS studies, as well as low-frequency and rare variants at parkinsonism-associated genes in the MDSgene database for their association with individual clinical characteristics and test scores at baseline assessment in our community-based PD patient cohort: age at onset, disease duration, Unified Parkinson's Disease Rating Scale I-VI, cognitive status, initial and baseline motor and non-motor symptoms, complications of levodopa therapy, comorbidities and family history of neurological disease with one or more than one affected family members. We find that in most cases an individual common PD-risk SNP identified in GWAS is associated with only a single clinical feature or test score, while gene-level tests assessing low-frequency and rare variants reveal genes associated in either a unique or partially overlapping manner with the different clinical features and test scores. Protein-protein interaction network analysis of the identified genes reveals that while some of these genes are members of already identified protein networks others are not. These findings indicate that genetic risk factors for PD differentially affect the phenotypic presentation and that genes associated with PD risk are also differentially associated with individual disease phenotypic characteristics at baseline. These findings raise the intriguing possibility that different SNPs/gene effects impact discrete phenotypic characteristics. Furthermore, they support the hypothesis that different gene and protein-protein interaction networks that underlie PD risk, the PD phenotype, and the neurodegenerative process leading to the disease phenotype, and point to the significance of the genetic background on disease phenotype.

Highlights

  • Parkinson’s disease (PD), the second most common neurodegenerative disease, has an insidious onset and a long pre-symptomatic and symptomatic course

  • We find that common SNPs from PD-risk genes identified in genome-wide association studies (GWAS) are individually associated with a range of clinical features: family history of dementia, the presence of hallucinations, bradykinesia, depression, orthostatism, disease subtype, and complications of levodopa therapy

  • We hypothesized that SNPs which have been previously demonstrated to show significant associations with PD-risk using large GWAS and low frequency and rare variants at parkinsonism-associated genes identified in the MDSgene database [19] differentially contribute to discrete baseline clinical parameters/symptoms. We evaluated their association in two well-characterized patient cohorts [MEPD [20] and DodoNA [23]] where individual clinical symptoms and objective test scores were obtained at baseline using structured clinical documentation support (SCDS) tools embedded in the electronic medical record (EMR)

Read more

Summary

Introduction

Parkinson’s disease (PD), the second most common neurodegenerative disease, has an insidious onset and a long pre-symptomatic and symptomatic course. The constellation of clinical symptoms is variable both in terms of symptom combination and temporal profile This variability has led to phenotypic classification according to different disease characteristics. A commonly accepted classification is based on motor symptoms: disease subtypes include a tremor-predominant, akinetic/rigid, and mixed subtype [1]. Simuni et al [3] reported that, for the Primary Progression Markers Initiative (PPMI) PD cohort, higher baseline non-motor scores were associated with female sex and a more severe motor phenotype. Mollenhauer et al [5] in their analysis of the De Novo Parkinson (DeNOPA) cohort, reported that baseline predictors of worse progression of motor symptoms included male sex, orthostatic blood pressure drop, diagnosis of coronary artery disease, arterial hypertension, elevated serum uric acid, and CSF neurofilament light chain.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.